Highlights the growing clinical importance of methamphetamine-associated cardiomyopathy and the need for further research into its management and prognosis.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to rising methamphetamine cardiomyopathy; leaves open gaps in incidence, risk factors, therapy, and prognosis.
Methamphetamine and related compounds are now the second most commonly used illicit substance worldwide, after cannabis. Reports of methamphetamine-associated cardiomyopathy (MAC) are increasing, but MAC has not been well reviewed. This analysis of MAC will provide an overview of the pharmacology of methamphetamine, historical perspective and epidemiology, a review of case and clinical studies, and a summary of the proposed mechanisms for MAC. Clinically, many questions remain, including the appropriate therapeutic interventions for MAC, the incidence and prevalence of cardiac pathology in methamphetamine users, risk factors for developing MAC, and prognosis of these patients. In conclusion, recognition of the significance of MAC among physicians and other medical caregivers is important given the growing use of methamphetamine and related stimulants worldwide.
No takes yet. Share an insight, caveat, or question.
Won et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: